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Summary 20 
Background 21 
Buruli ulcer can cause disfigurement and long-term loss-of-function. It is under-diagnosed and 22 
under-reported, and its current distribution is unclear. We aimed to synthesise and evaluate data on 23 
BU prevalence and distribution. 24 
Methods  25 
We conducted a systematic review of BU prevalence, and used an evidence consensus framework to 26 
describe and evaluate evidence for BU distribution worldwide. We searched online databases from 27 
inception to 06/08/2018 for records of BU and M. ulcerans detection, with no limits on study type, 28 
date, or location. We included population-based surveys presenting BU prevalence estimates in the 29 
systematic review, extracting prevalence estimates with 95% CIs. We extracted geographical data on 30 
the occurrence of BU cases and M. ulcerans detection from studies of any type. Occurrence records, 31 
reports to WHO and the Global Infectious Diseases and Epidemiology Network, and national BU 32 
surveillance data were included in an evidence consensus framework to grade the strength of 33 
evidence for BU endemicity. This study is registered with PROSPERO, number CRD42018116260. 34 
Findings 35 
2,763 titles met the search criteria.  We extracted prevalence estimates from ten studies and 36 
occurrence data from 208. Prevalence estimates within study areas ranged from 3.2- 26.9 per 37 
10,000. There was evidence of BU in 32 countries and consensus on presence in 12.    38 
Interpretation 39 
The global distribution of BU is uncertain, and potentially wider than currently recognised. These 40 
maps represent the strongest available evidence on BU distribution to date, and have many 41 
potential applications, from directing surveillance activities to informing burden estimates.  42 
Funding 43 
The AIM Initiative was the sole funder. 44 
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Background (343 words) 46 
Buruli ulcer (BU) is a neglected tropical disease caused by the environmental pathogen 47 
Mycobacterium ulcerans. It primarily occurs in West and Central Africa, but also in parts of Asia, 48 
South America, the Western Pacific and Australasia.1,2  It is considered an important public health 49 
problem due to the characteristic necrotic ulcers it causes, and the scarring and deformity which can 50 
persist after treatment.3 Although its mode of transmission is not fully understood, contact with 51 
slow-flowing, stagnant, or disturbed water bodies is an important risk factor.4  52 
BU was reported in 34 countries from 1960-2015,4 but there is lack of consensus on where 53 
transmission currently occurs. Ten countries reported a total of 1,864 cases to the WHO in 2016,1 54 
but this is recognised to reflect a small proportion of the total burden. Cross-sectional surveys within 55 
endemic countries have demonstrated under-reporting of BU,5-7 for reasons including the chronic, 56 
stigmatising nature of the disease, its rural distribution, patients’ lack of access to healthcare or 57 
preference for traditional healers, and lack of awareness or resources within health systems.4,8 58 
Misdiagnosis may also contribute to under-detection: BU has a range of non-specific presentations 59 
which can be confused with other skin conditions, especially in the absence of confirmatory tests.9,10  60 
Therefore, available data does not provide a full or accurate representation of BU burden and 61 
distribution: essential information for targeting of active case detection, which is a key part of 62 
control,3 and for directing resources for case management.  63 
Estimating the global burden and population at risk of BU requires detailed information on the 64 
geographical limits and prevalence of the disease. We aimed to synthesise available data on BU 65 
prevalence and occurrence and environmental occurrence of M. ulcerans, including WHO reports, 66 
national surveillance programmes, the grey literature, and peer-reviewed literature. We undertook a 67 
systematic review of population-based studies reporting the prevalence of BU, providing a descriptive 68 
analysis of BU epidemiology within known-endemic areas. We used an evidence consensus 69 
approach11,12 to delineate the overall distribution of previously reported cases and to quantify the 70 
strength of evidence for BU presence or absence in every country worldwide.  71 
  72 
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Methods (1266 words) 73 
This review is registered in the PROSPERO International Prospective Register of systematic reviews; 74 
CRD42018116260. 75 
Information sources  76 
Data sources included peer-reviewed literature, conference proceedings and abstracts and 77 
government reports (grey literature), data reported to WHO from 2006-2017,1 data reported 78 
through the GIDEON network,13 and surveillance datasets from national BU programmes in 79 
Cameroon, Ghana, Nigeria and Togo. Peer-reviewed literature was identified from searches of 80 
PubMed and Web of Science databases, updated on 06/08/2018. Additional publications were 81 
identified from reference lists of identified papers.  82 
Literature Search  83 
We used the search terms (OR): “Buruli ulcer*”, (“Mycob* AND ulcer*”), “Bairnsdale ulcer”. There 84 
were no limits on publication date, study type, or location. We included English, French, and Spanish 85 
language publications. Details in section S.1.1, Supplementary File. 86 
Eligibility criteria  87 
Population-based BU surveys were included in the systematic review if they reported the prevalence 88 
of BU within a defined geographical area, or information allowing this to be calculated.  89 
Publications were eligible for inclusion in the evidence consensus if they reported geographical 90 
locations with evidence of M. ulcerans infection in humans or animals, or detection of M. ulcerans in 91 
animal and environmental samples.  92 
There were no limits on publication date, participant population, study type or location. Articles that 93 
did not report original data were excluded.  94 
Study selection  95 
Titles were screened to exclude non-relevant publications. Abstracts of selected records were 96 
screened to identify papers which apparently fulfilled selection criteria. Full texts of selected articles 97 
were read to identify studies meeting the selection criteria. Studies that recruited patients from 98 
health facilities or used strains of M. ulcerans isolated from clinical samples were included in the 99 
evidence consensus framework only if patients’ home addresses were provided. Cases with recorded 100 
travel history to several endemic regions were excluded. If a dataset was duplicated in numerous 101 
papers, the most comprehensive was included.  102 
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Data extraction 103 
Data from surveillance datasets and selected publications was extracted into a bespoke Microsoft 104 
Excel spreadsheet used for the Global Atlas of Helminth Infections.14 The original spreadsheet was 105 
piloted on a subset of studies, and then developed. Authors were contacted for additional data if 106 
community-level results were not presented. The data extraction was performed by a single author 107 
and checked by a second one. Data extracted included: i) the number or prevalence of cases, ii) the 108 
sample size and survey coverage (for population-based studies) iii) the case detection method 109 
(survey, case search, passive detection), iv) the recording date, v) the diagnostic procedure, including 110 
any confirmatory tests (polymerase chain reaction (PCR) for M. ulcerans gene targets; Ziehl Neelsen 111 
(ZN) staining; culture for M. ulcerans; histopathological analysis) and their results, and vi) the 112 
location of origin (patient residence or endemic area visited if the case originated from a non-113 
endemic area). Areas described as ‘endemic’, with no information on case detection, were not 114 
included.  115 
Data extracted on environmental detection of M. ulcerans included: i) sample date and location, ii) 116 
sample type (water, soil, plant, animal- clinical, animal- faeces), iii) taxonomic details for animal 117 
samples, iv) confirmatory tests, and v) numbers of samples tested and positive. 118 
Geographic coordinates of occurrence locations were extracted if were provided in the publication. 119 
Otherwise, point locations were georeferenced remotely (section S.1.2, Supplementary File). Point 120 
locations that could not be georeferenced were linked to the lowest administrative level provided in 121 
the publication. Polygon areas corresponding to first and second administrative divisions were linked 122 
to units defined in the Database of Global Administrative Areas.15 123 
Summary measures  124 
The principal summary measure for the systematic review was BU prevalence. The quality of 125 
prevalence studies was assessed using a framework based on the Newcastle-Ottawa score,16  126 
adapted from a systematic review of podoconiosis prevalence17 (S.3. Supplementary File). This took 127 
account of the sampling frame, response rate, diagnostic specificity, and statistical analysis. The risk 128 
of outcome bias was assessed according to whether sampling was done at random or using 129 
convenience sampling within the study area. The number of studies from each country, relative to 130 
the number of cases reported to WHO, was used as an indicator of geographical bias between 131 
studies.  132 
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The outcome measures for the evidence consensus framework were BU and M. ulcerans occurrence. 133 
Occurrence locations were assigned local- and national-level quality scores reflecting 134 
contemporariness and specificity (S.1.3- S.1.4, Supplementary File). We used the number of studies 135 
included in the evidence consensus framework, and the number reporting laboratory confirmation, 136 
as indicators of geographical bias in reporting and study quality. 137 
Data Synthesis 138 
We extracted prevalence estimates from included surveys and calculated 95% confidence intervals 139 
(CIs) using Byar’s method.18 140 
Occurrence data was synthesised through an evidence consensus approach using a weighted scoring 141 
system, following that used to determine the global distribution of other diseases.11,12 Separate 142 
frameworks were used to assess the evidence for BU presence or absence at national level (Figure 143 
1), evidence for BU presence at sub-national level (Figure 2), and evidence for environmental 144 
occurrence of M. ulcerans at sub-national level (section S.1.5, Supplementary File).  145 
National level 146 
The major features for the national evidence framework were: 147 
- Health reporting organisations: Countries were assigned a score based on recent and historical 148 
reporting to WHO and reports through GIDEON. 149 
- Occurrence data quality: Each country was assigned the highest data quality score of occurrence 150 
records within it.  151 
- Number of cases: The number of cases reported at each location was weighted by the local-level 152 
data quality score, and the weighted totals were aggregated to national level.  153 
- Evidence for absence: In countries with no cases reported, the consensus score was designed to 154 
quantify the evidence for BU absence, reflecting the possibility of under-reporting due to (i) 155 
weak surveillance capacity, or (ii) misdiagnosis as known endemic diseases with similar 156 
presentations19 (confounding diseases)  (Figure 1B). As a proxy for surveillance and diagnostic 157 
capacity, health expenditure (HE) reported by WHO20 was categorised as low (<$100), medium 158 
($100≤HE<$500) or high (HE≥$500), following the approach of previous authors and supported 159 
by evidence that higher HE is associated with better health system performance21. 160 
 161 
The confounding diseases with available evidence on their global distribution were: cutaneous 162 
leishmaniasis (CL),12,22 leprosy,23 lymphatic filariasis (LF),14 onchocerciasis,24 tropical ulcer (TU)2 163 
and yaws25. Estimates of the frequencies of the common presentations of these diseases and BU 164 
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were obtained from literature review and expert opinion.24,26-29 For each confounding disease, 165 
the frequency of each presentation shared with BU was multiplied by the frequency of the 166 
presentation among BU cases, and the products summed to generate a symptom overlap score 167 
(Table S1, Supplementary File).  168 
 169 
For each country, the symptom overlap scores for its endemic confounding diseases were 170 
summed, then down-weighted if HE was high or medium. This score was added to an ordinal HE 171 
score reflecting likelihood of under-detection/ non-reporting.   172 
Figure 1 approximately here173 
 174 
Sub-national level 175 
Each upper administrative level was assigned the highest local-level evidence quality score of the 176 
occurrence records which fell within it or within 5km distance of its boundaries, and a score 177 
reflecting total number of cases within the unit (Figure 2).  178 
 179 
Figure 2 approximately here180 
 181 
Environmental occurrence of M. ulcerans 182 
Environmental detection records were assigned to the upper administrative unit15 they fell within. 183 
Each unit was assigned the highest evidence quality score of records within it, and a score reflecting 184 
the total number of detection records within it, weighted by evidence quality score (Table S2, 185 
Supplementary File).  186 
Role of the funding source  187 
The AIM Initiative was the sole funder of this work. The AIM Initiative facilitated connections with 188 
disease control programmes for data transfer, but had no input in the systematic review or decision 189 
to publish. Hope Simpson had full access to all data in the study and final responsibility for the 190 
decision to submit for publication. 191 
Kebede Deribe is supported by the Wellcome Trust [grant number 201900] as part of his 192 
International Intermediate Fellowship. The Wellcome Trust has not played any role in the design, 193 
conduct, analysis, or writing up of the study.  194 
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Results (918 words) 195 
Study selection 196 
The literature search identified 2,849 records after de-duplication (Figure 3). Another 86 were 197 
identified through other sources. The most common reason for exclusion was lack of information on 198 
patient origin. Full text was unavailable for 46 studies. Ten BU prevalence surveys were included in 199 
the systematic review.7,8,30-35 Occurrence data was extracted from 208 publications and five 200 
surveillance datasets. 201 
 202 
Figure 3 approximately here 203 
 204 
Study characteristics  205 
Three surveys conducted in Cameroon, two in each of Benin, Cote d’Ivoire and Ghana, and one in 206 
the DRC (Table 1) were included. The largest was a national survey in Cote d’Ivoire, covering an 207 
estimated 14,500,000 people.5 208 
 209 
Seven surveys provided explicit details on the sampling frame. All surveys were community-based 210 
and aimed to reach the entire population of chosen communities. Seven covered the entire study 211 
area, one surveyed randomly selected communities within the study area, one surveyed a 212 
convenience sample of communities and one used random and convenience sampling. Only one 213 
reported the survey coverage.8 Five reported laboratory confirmation of all or a subset of cases, five 214 
used clinical case definitions. Only one study reported prevalence with 95% CIs.8  215 
Overall prevalence estimates within the study area ranged from 3.2- 26.9 cases per 10,000. The 216 
highest reported community prevalence of BU was 2,200 per 10,000.34217 
 218 
Table 1 approximately here 219 
 220 
Evidence consensus  221 
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Human cases were recorded from 32 countries, and inferred from two further countries from which 222 
strains were reported to have been isolated (Iran and Malaysia) 36,37. Most cases (94·9%) were from 223 
the African (AFRO) region, 5·6% were from the West Pacific (WPRO) region, and less than 1% were 224 
from other WHO regions. Evidence of M. ulcerans in environmental and animal samples was 225 
reported from nine countries. A summary of data extracted from all publications is provided in Table 226 
S.3 of Supplementary File. 227 
Cases were recorded from 1952- 2017, with the greatest number detected in 1999 (3,401). From 228 
1952- 1998, between zero and five countries each year had evidence of BU based on peer-reviewed 229 
literature. The disease was identified in nine countries in 1999. Including data reported to WHO, 230 
available from 2002, between twelve and eighteen countries each year had evidence of BU. 231 
Laboratory confirmation of at least one case was reported by 71% of studies included, and 62.5% 232 
used PCR. However, most occurrence records (77%) were categorised as clinically diagnosed only, 233 
because laboratory results were not disaggregated by unique locations. 234 
Symptom overlap scores for the confounding diseases are shown in Table 2. TU had the highest 235 
score, reflecting the high frequency of ulcers among BU and TU.2,35 BU was considered less likely to 236 
be misdiagnosed as CL or yaws, which present a lower frequency of ulcerous forms.26,27 237 
Onchocerciasis, leprosy and LF had symptom overlap scores below 6%. 238 
Full results of the evidence consensus framework are provided at country level in Supplementary 239 
File, Table S.5. 240 
 241 
Table 2 approximately here 242 
 243 
We identified consensus on BU presence in twelve countries, which collectively reported 34,890 244 
cases to WHO from 2002- 2016 (96·2% of all cases reported to WHO in this period). Australia and 245 
Japan were the only non-African countries with consensus on presence (Figure 4).  246 
The African countries with evidence of BU were mostly clustered in a block covering much of Central 247 
and West Africa. Countries around this block generally had weaker evidence for absence, with a 248 
higher number of endemic confounding diseases and lower HE. In the AMRO region, evidence of BU 249 
was strong in French Guiana and Peru, and moderate in Brazil, Mexico and Suriname. Despite strong 250 
evidence of BU cases from French Guiana in literature reports, the disease has never been reported 251 
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to WHO, so full consensus on endemicity was not reached through the framework. There was 252 
moderate evidence for BU in China. Endemicity status was indeterminate in Burkina Faso, Ethiopia, 253 
Honduras, Indonesia, Malawi, Malaysia and Suriname. Niger, Eritrea, the Gambia, and Mauritania, all 254 
in the AFRO region, had the weakest evidence for absence, being endemic for CL and TU, and having 255 
low health expenditure. Fourteen other countries- of which 12 were in Africa- had weak evidence for 256 
absence.   257 
Figure 4 approximately here 258 
 259 
Sub-national areas with evidence for endemicity were mostly clustered within equatorial, humid 260 
tropical and tropical climate zones of West and Central Africa (Figure 5). Areas with evidence for BU 261 
in Eastern, Southern, and non-coastal Central Africa, and other parts of the world, were more 262 
isolated (Figures 5 and 6).  263 
 264 
Figure 5 approximately here 265 
Figure 6 approximately here 266 
 267 
Buruli ulcer in animals and M. ulcerans in the environment 268 
The areas with evidence of M. ulcerans in animal and environmental samples are shown in Figure 7. 269 
BU disease was reported in wild and domestic animals in Australia, Benin, Cameroon and Ghana, and 270 
M. ulcerans DNA has been detected in faecal samples from animals in Australia (details and 271 
references in Table S.4). DNA from mycolactone-producing environmental bacteria has been 272 
identified in biotic and abiotic samples from waterbodies in eight BU endemic countries, and the 273 
United States of America (details and references in Table S.4). However, it is not clear if the 274 
American strains would be capable of causing BU disease in humans.  275 
 276 
Figure 7 approximately here 277 
 278 
 279 
Discussion (1011 words) 280 
We have collated available on BU prevalence and occurrence, and evidence of M. ulcerans in animals 281 
and the environment. The evidence consensus framework applied has allowed us to expand on 282 
existing maps of BU distribution 2,38 in several ways. The maps presented include evidence from a 283 
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wider range of sources, provide finer resolution, and quantify the strength of evidence for BU 284 
presence, as well as absence in countries where BU has not been reported.  285 
There have been few BU prevalence surveys, and most of those identified did not report detailed 286 
statistical analysis or indicators such as coverage. We did not undertake a meta-analysis because 287 
of the heterogeneous nature of compiled studies. Furthermore, most studies included were 288 
conducted in areas assumed to have a high rate of BU, so a summary prevalence would tend to 289 
overestimate the disease burden in the overall population. 290 
Prevalence estimates reported by population-based studies were high relative to incidence data 291 
reported through WHO. This is likely to reflect underreporting of BU through routine systems, but 292 
the studies included may have overestimated BU prevalence due to sampling bias. Two of the ten 293 
studies included7,35 used convenience sampling as part of the study design, which implies a risk of 294 
bias in the estimated prevalence. Five studies reported clinical diagnosis according to WHO 295 
guidelines and five used laboratory confirmation to confirm all or a subset of cases. There was 296 
geographical bias across the studies included, representing only five countries out of the 32 297 
identified as having evidence for BU.  298 
Our investigation identified consensus on BU presence in eight of the ten countries accounting for 299 
97% of BU cases reported to WHO from 2007- 2016. However, the maps presented demonstrate 300 
significant remaining uncertainty on the global distribution of BU. There was indeterminate or 301 
moderate quality evidence of BU in fifteen countries that had not reported data to WHO from 2007- 302 
2016.  303 
The national and sub-national evidence consensus maps demonstrate large contiguous areas of 304 
potential endemicity, both within and between countries, particularly in Central and Western Africa. 305 
Evidence for BU presence was generally strongest in these contiguous areas. This is likely to be partly 306 
due to environmental similarity in terms of suitability, and partly due to increased emphasis on case 307 
detection in areas established as endemic.  308 
The area of BU presence defined by the sub-national map of BU distribution in Africa (Figure 5) was 309 
more restricted than that defined by the map of national-level endemicity (Figure 4). This reflects 310 
the focal and restricted distribution of BU,39 and the lower availability of data at subnational level: in 311 
some countries, the only available data was that reported to WHO, with no information on sub-312 
national distribution. Given the recognised scale of BU under-reporting, it is likely that this map 313 
underestimates the scale of BU distribution. 314 
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Countries which had not reported BU cases, but were close to those that had, generally had weaker 315 
evidence for absence than countries located further from areas of BU endemicity. This trend was 316 
apparent in Africa, South America, and the South East Asia and Western Pacific regions, and reflects 317 
spatial clustering of countries with lower health expenditure and numerous co-endemic tropical 318 
diseases, irrespective of their evidence for BU. The proximity of BU-endemic countries to those with 319 
lowest evidence for BU absence adds further weight to the possibility that BU may occur undetected 320 
in the latter group, due to cross-border transmission and environmental similarity of neighbouring 321 
countries.  322 
Limitations 323 
While the maps provide finer detail on the distribution of BU than current official maps, they still 324 
mask the underlying epidemiology of BU. Areas identified as endemic may in fact contain only a few 325 
localised cases of BU, and be mostly unsuitable for the disease. Due to the focal nature of BU,39 326 
point-level data on disease occurrence is needed to support investigation into its spatial 327 
epidemiology. It is hoped that the maps and assembled geographic dataset will support such 328 
research in the future.  329 
Studies on M. ulcerans environmental occurrence were limited, and many did not apply sufficiently 330 
specific tests to differentiate M. ulcerans from other environmental mycobacteria. Therefore, the 331 
maps of evidence for environmental occurrence of M. ulcerans do not provide a complete 332 
representation of environmental suitability for the bacterium. Although we assigned the maximum 333 
possible evidence quality score to clinical cases confirmed by PCR and environmental occurrences 334 
confirmed by q-PCR, these tests still entail a risk of false positives, as demonstrated by an external 335 
quality assessment including several reference laboratories which performed confirmatory testing in 336 
studies we included.40  337 
There was marked geographical bias in the occurrence records, reflecting different levels of research 338 
and surveillance activity between countries. Further analysis of the data underlying this work should 339 
account for this bias. In the context of this study, this bias is expected to have impacted areas where 340 
there were few studies, but not where there were many studies, since additional studies would not 341 
change the outcome measure unless they provided higher quality data.  342 
Implications 343 
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The areas with highest consensus for presence are presumably most suitable for BU transmission, 344 
and would be targets for surveillance and research since they represent known disease foci. Some 345 
countries with strong evidence for BU are not shown in the current WHO map of BU,38 346 
demonstrating that the disease is more widely distributed than the official map suggests. This has 347 
important implications for understanding and communicating the global burden of BU. We have also 348 
expanded upon the WHO map of BU by qualitatively grading the strength of evidence for 349 
endemicity. In doing so we have identified numerous countries with moderate or indeterminate 350 
evidence of BU, and those with weakest evidence for its absence, which may require further 351 
investigation to clarify the global distribution of BU. Active case finding in areas which have 352 
previously reported BU, and close to those currently reporting, should be prioritised. The assembled 353 
point-level dataset represents a novel resource for continent-wide exploration of environmental and 354 
biological predictors of BU, and estimation of the global burden and population at risk. The 355 
information provided by investigations such as these will help to target future control efforts and 356 
evaluate their impact. 357 
  358 
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Figure 1: Evidence consensus framework used to assess strength of evidence for BU presence and absence at national level  
 
Part A used for all countries, part B additionally for countries with no evidence of reported cases. Numbers in bold show each constituent’s maximum score. 
*Score was adjusted post-hoc for countries from which M. ulcerans strains had been isolated, if no cases meeting inclusion criteria were identified.  
PCR = polymerase chain reaction. ZN = Ziehl Neelsen staining. 
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Figure 2: Evidence consensus framework used to assess strength of evidence for BU presence at sub-national level  
 
Numbers in bold show each constituent’s maximum score. 
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Figure 3: Selection of eligible studies 
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Figure 4: Evidence consensus for BU presence and absence worldwide 
  
BU endemicity 
Evidence consensus score
100 (consensus presence)
75 - 99 (very strong)
50 - 74 (strong)
25 - 49 (moderate)
0 - 24 (indeterminate)
-24 - -1 (weak)
-49 - -25 (moderate)
-74 - -50 (strong)
-99 - -75 (very strong)
-100 (consensus absence)
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Figure 5: Evidence for Buruli Ulcer Endemicity at National and Upper Sub-National Levels in Africa
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Figure 6: Evidence for Buruli Ulcer Endemicity at National and Upper Sub-National Levels in Central and South America and the Pacific Region. 
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Figure 7: Evidence for Environmental Occurrence of Mycobacterium ulcerans at Upper Sub-National Level and for Buruli ulcer endemicity at national 
level in West and Central Africa, the Western Pacific Region, and South America
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Table 1: Characteristics of population-based BU prevalence surveys included in the systematic review 
Main author, 
year published 
Country 
Year of 
survey 
Location Study design Case ascertainment 
N. active 
cases 
Sample 
size 
Prevalence (95% CI) 
Quality 
score  
Johnson et al., 
200541 
Benin 2004 Lalo commune 
Exhaustive preparatory phase 
followed by validation of 
suspected cases 
Clinical diagnosis following 
WHO guidelines 
160 86,819 18.4 (15.7- 21.5) 4 
Sopoh et al., 
201031 
Benin 2006 Zè district 
Exhaustive preparatory phase 
followed by validation of 
suspected cases 
Clinical diagnosis following 
WHO guidelines 
222 82,450 26.9 (23.5- 30.7) 4 
Noeske et al., 
20047 
Cameroon 2001 
Ayos and 
Akonolinga 
health districts 
Exhaustive survey in 
convenience sample of 
communities with suspect cases 
Clinical diagnosis, a subset 
confirmed by PCR and/or ZN 
staining 
202 98,500 20.5 (17.8- 23.5) 2 
Porten et al., 
20098 
Cameroon 2007 
Akonolinga 
district 
Exhaustive survey in a random 
selection of communities 
Clinical diagnosis following 
WHO guidelines, active and 
total cases reported separately 
56 26,679 21.0 (15.9- 27.3) 5 
Bratschi, 201342  Cameroon 2010 
Bankim Health 
District 
Exhaustive survey of health 
district 
Clinical diagnosis, a subset 
confirmed by PCR 
25 48,962 5.1 (3.3- 7.5) 3 
Kanga 200143 
Côte 
d'Ivoire 
1995 Cote d’Ivoire 
Exhaustive survey of entire 
country 
Suspect cases identified by 
CHWs, confirmed by clinicians 
4,642 14,500,000 3.2 (3.1- 3.3) 2 
Ecra et al., 
200532 
Côte 
d'Ivoire 
1998 
Zoukoougbeu 
sub-prefecture 
Exhaustive survey of entire sub-
prefecture 
Nodules detected clinically, M. 
ulcerans confirmed by 
histopathological analysis 
54 47,742 11.3 (8.5- 14.8) 3 
Mavinga Phanzu 
et al., 2013 33 
DRC 2008 
Kimpese and 
Nsona-Mpangu 
Rural Health 
Zones 
Exhaustive preparatory phase 
followed by validation of 
suspected cases 
Clinical diagnosis following 
WHO guidelines, a subset 
confirmed by PCR 
259 237,418 10.9 (9.6- 12.3) 6 
Amofah et al., 
199334 
Ghana 1991 
Amansie West 
district 
Exhaustive survey of entire 
district 
Clinical diagnosis, a subset 
confirmed by ZN staining 
90 130,000 6.9 (5.6- 8.5) 4 
Ampah et al., 
201635 
Ghana 2013 Offin river valley 
Exhaustive survey in random 
sample (n=10) and convenience 
sample (n=3) of communities 
within 5km of the Offin River  
Clinical diagnosis in following 
WHO guidelines, a subset 
confirmed by PCR 
7 20,390 3.4 (1.4- 7.1) 6 
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PCR = polymerase chain reaction. ZN = Ziehl Neelsen staining. DRC = Democratic Republic of Congo. 1Prevalence of nodules only- did not include other 
forms of BU
 Table 2: Symptom overlap scores (0- 100) for diseases whose symptoms can also be caused by BU. 
Confounding disease Summed score 
Tropical Ulcer 70.9 
Cutaneous leishmaniasis 35.0 
Yaws 16.3 
Onchocerciasis 5.7 
Leprosy 3.6 
Lymphatic filariasis  0.5 
 
  
  
